Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells

Background: Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), have been widely applied in clinical and scientific research. Despite their effective antitumor effects in clinical tumor therapy, most tumors are still resistant to ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Jingyao, Xu, Haoran, Ma, Li, Li, Chunya, Qin, Wan, Chen, Xinyi, Yi, Ming, Sun, Li, Liu, Bo, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692903/
https://www.ncbi.nlm.nih.gov/pubmed/34976211
http://dx.doi.org/10.7150/thno.65828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692903/
https://www.ncbi.nlm.nih.gov/pubmed/34976211
http://dx.doi.org/10.7150/thno.65828

Ejemplares similares